Tag: docetaxel
Articles
- Latest research concerning side effects of chemotherapy
- Latest research concerning triple negative breast cancer prognosis
- Latest research on factors influencing Taxol (paclitaxel) effectiveness
- What should breast cancer patients eat during Taxol (paclitaxel) chemotherapy?
News
- Bisphosphonates for treating osteoporosis may significantly reduce risk of breast cancer
- Brassica compound DIM inhibits breast cancer cell growth synergistically with Taxotere
- Fish oil component can increase survival time for Stage IV breast cancer patients
- Muscle and joint pain are common during taxane chemotherapy for breast cancer
- Neutropenia during chemotherapy predicts favorable breast cancer outcome
- Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
- Possible toxic side effects of chemotherapy
- Resveratrol increases effectiveness of Taxotere (docetaxel) and Adriamycin (doxorubicin)
- Survival times for metastatic breast cancer have been improving
Foods
Studies
- 3, 3'-diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1
- Addition of Bevacizumab to Conventional Therapy Improved Progression-Free Survival in HER2-Positive Breast Cancer
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo
- d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis
- Differential response from neoadjuvant chemotherapy across breast cancer subtypes
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
- Exogenous supplementation with [omega]-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
- Fifteen-year trends in metastatic breast cancer survival in Greece
- Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer
- Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
- Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
- Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy
- Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in northeast china
- Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer
- Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro
- Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane